Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

NARecruitingINTERVENTIONAL
Enrollment

264

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

October 1, 2026

Conditions
Type 2 Diabetes MellitusType2diabetesDiabetes Mellitus, Type 2DiabetesType 2 Diabetes
Interventions
DEVICE

ReCET Treatment

Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.

DEVICE

Sham Procedure

The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.

Trial Locations (45)

2006

RECRUITING

Royal Prince Alfred Hospital, Camperdown

2028

RECRUITING

The BMI Clinic, Double Bay

2065

RECRUITING

Royal North Shore Hospital, Saint Leonards

3004

RECRUITING

Baker Heart and Diabetes Institute, Melbourne

3065

RECRUITING

St Vincent's Hospital Melbourne, Fitzroy

3128

RECRUITING

Eastern Health - Box Hill Hospital, Box Hill

21287

RECRUITING

John Hopkins, Baltimore

32224

RECRUITING

Mayo Clinic, Jacksonville

32804

RECRUITING

Advent Health, Orlando

32806

RECRUITING

Orlando Health, Orlando

33009

RECRUITING

Velocity Clinical Research, Hallandale Beach, Hallandale

33140

RECRUITING

Quantum Clinical Research, Miami Beach

33166

RECRUITING

Universal Axon Clinical Research LLC, Miami

RECRUITING

University of Miami, Miami

33407

RECRUITING

Health Synergy Clinical Research, West Palm Beach

34761

RECRUITING

West Orange Endocrinology, Ocoee

35205

RECRUITING

University of Alabama, Birmingham

35209

RECRUITING

Central Alabama Research, Birmingham

43210

RECRUITING

The Ohio State University- Wexner Medical Center, Columbus

50266

RECRUITING

Iowa Diabetes and Endocrinology Research Center, West Des Moines

50325

RECRUITING

Heartland Medical Research, Inc., Clive

55905

RECRUITING

Mayo Clinic, Rochester

60201

RECRUITING

NorthShore University Health System, Evanston

75115

RECRUITING

Epic Medical Research, DeSoto

75230

RECRUITING

Velocity Clinical Research, Dallas, Dallas

75235

RECRUITING

Southwest Medical Center, Dallas

RECRUITING

University of Texas Southwestern Medical School - William P. Clements Jr. University Hospital, Dallas

77030

RECRUITING

Houston Methodist Research Institute, Houston

77054

RECRUITING

Juno Research, LLC, Houston

77401

RECRUITING

The University of Texas Health Science Center at Houston, Bellaire

77479

RECRUITING

Mt. Olympus Medical Research, Sugar Land

78229

RECRUITING

Diabetes & Glandular Disease Clinic, P.A., San Antonio

RECRUITING

IMA Clinical Research - San Antonio, San Antonio

78613

RECRUITING

Velocity Clinical Research - Austin, Austin

78681

RECRUITING

Texas Diabetes & Endocrinology, P.A., Round Rock

78712

RECRUITING

Dell Medical School, Austin

78745

RECRUITING

IMA Clinical Research - Austin, Austin

90048

RECRUITING

Cedars-Sinai Medical Center, Los Angeles

90065

RECRUITING

UCLA, Los Angeles

90247

RECRUITING

Velocity Clinical Research, Gardena, Gardena

91402

WITHDRAWN

Velocity Clinical Research, Panorama City, Panorama City

92663

RECRUITING

Hoag Memorial Hospital Presbyterian - Digestive Health Institute, Newport Beach

08103

RECRUITING

Cooper Health System, Camden

08901

RECRUITING

Robert Wood Johnson Medical School, New Brunswick

Unknown

RECRUITING

Austin Health, Heidelberg

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Endogenex, Inc.

INDUSTRY

NCT06267391 - Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | Biotech Hunter | Biotech Hunter